Clinical Trial

A Study of BL-M11D1 in Patients With Relapsed/Refractory Myelodysplastic Syndromes

Name: A Study of BL-M11D1 in Patients With Relapsed/Refractory Myelodysplastic Syndromes — clinical trial record (NCT07591168)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This study is an open-label, multicenter, non-randomized Phase Ib/II clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of BL-M11D1 for injection in patients with relapsed/refractory myelodysplastic syndromes.

Trial Details

NCT Number	NCT07591168
Lead Sponsor	Sichuan Baili Pharmaceutical Co., Ltd. Collaborators: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Conditions	Myelodysplastic Syndromes
Enrollment	92 participants
Start Date	2026-05
Primary Completion	2028-12 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2026-05-15